Off-the-shelf immunotherapy targets kidney cancer
UCLA Health - 29-Aug-2025Engineered NKT cells attack tumours and reshape defences, offering new hope for kidney cancer
Join the club for FREE to access the whole archive and other member benefits.
Engineered NKT cells attack tumours and reshape defences, offering new hope for kidney cancer
High-speed data analysis could unlock hidden patterns to design new cancer vaccines
Real-time tissue scanning may cut radiotherapy need and preserve quality of life
Study finds pancreatic, lung, and stomach cancers see little progress in long-term survival
Jab targeting KRAS mutation kept some patients cancer-free for over 15 months
New dual-bacteria therapy shows potent, safe cancer-killing power in immunocompromised models
Certified AI app offers safe, reliable skin cancer risk checks via smartphone photos
Doctors can now tailor treatments more precisely with these insights
AI flagged 40K+ scans/month, avoided 1,400 CTs, and helped detect 2,000 lung cancers early
Without changes, liver cancer cases and deaths could nearly double by 2050
Digital cells forecast disease and drug response
RP1 shrinks deep skin tumours and may soon win FDA approval as a new melanoma treatment
Some herbal medicines also showed risky DNA changes
New RNA method may cut costs and simplify cancer treatment by skipping lab-grown cell steps
New MRI-based tech may better detect tumour changes without contrast dye in brain cancer patients
New patch collects molecular data without cutting tissue, enabling faster, safer disease diagnosis
New therapy Blenrep offers hope by tripling remission time in multiple myeloma patients
FaceAge estimates health from photos, aiding cancer care and improving survival predictions
Genetic traces of cancer may be detectable in blood up to three years before diagnosis, study finds
Despite major progress, cancer remains the UK's top killer with rising case numbers expected by 2040
Scientists believe exercise helps control inflammation, hormones, and immunity
AI reads routine mammograms to deliver personalized 5‑year breast cancer risk scores
Pembrolizumab doubled cancer-free survival from 2.5 to 5 years and cut spread risk by 10%
New liquid biopsy accelerates targeted cancer treatment
Biotech pivots to drug combo after monotherapy safety and efficacy setbacks